PolyPid's Innovative Presentation at Key Biopharma Conference

Author: Evelyn Baker Updated: 09-02-2025 08:47 AM

PolyPid's Participation in a Notable Conference

PolyPid Ltd., a leading biopharmaceutical company, is committed to enhancing surgical outcomes with its innovative approaches. Recently, the company announced its participation in a vital conference, showcasing its advancements in the field.

Details of the Presentation

Dalit Hazan, the Deputy CEO and Executive Vice President of Research, Development, Clinical, and Regulatory Affairs, will represent the company. The presentation is scheduled for a prime slot on September 7 during the highly anticipated Session 1, focused on 'Advances in Targeted and Controlled Drug Delivery.'

Significance of the Presentation

During her talk, Hazan will unveil the topic titled 'Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial'. This presentation aims to provide insights into how PolyPid’s unique methods are changing the landscape of drug delivery in surgical environments.

About PolyPid Ltd.

Founded with the goal of improving surgical outcomes, PolyPid Ltd. leverages its proprietary PLEX technology, which combines Polymer-Lipid Encapsulation technology with Active Pharmaceutical Ingredients (APIs). This cutting-edge approach enables healthcare professionals to administer therapeutics that release drugs at tailored rates over extended periods, addressing significant clinical needs.

Innovative Pipeline

PolyPid is progressing towards the submission of a New Drug Application for D-PLEX???, its lead product candidate aimed at preventing colorectal surgical site infections. Strong results from Phase III trials have set the stage for this exciting next step in 2026. Additionally, the company's robust pipeline spans various therapeutic areas, including oncology, obesity, and diabetes.

Meeting Key Stakeholders

Attending this conference not only signifies PolyPid's dedication to innovation but also provides an opportunity to engage with leading experts, researchers, and investors in the biopharma space. Such interactions can further enhance PolyPid’s strategic partnerships and educational outreach.

Company's Future Requests

Looking ahead, the company aims to explore further advancements in localized drug administration, which can significantly impact patient care. Dialogues established at these conferences could lead to collaborative projects that align with PolyPid's mission.

Company Contact Information

For more information about PolyPid, contact:
Ori Warshavsky
908-858-5995
IR@Polypid.com

Frequently Asked Questions

What is PolyPid Ltd. known for?

PolyPid Ltd. specializes in surgical therapeutics, focusing on local, prolonged drug delivery systems to improve surgical outcomes.

Who will present at the conference?

Dalit Hazan, Deputy CEO and EVP, will deliver a presentation on innovative drug delivery methods.

What technology does PolyPid use?

The company employs PLEX technology, integrating Polymer-Lipid Encapsulation with Active Pharmaceutical Ingredients for optimized drug delivery.

What are the future prospects for PolyPid?

PolyPid is set to submit a New Drug Application for its lead product, aiming for significant impact in preventing surgical site infections.

How can I contact PolyPid?

Interested parties can reach out via email at IR@Polypid.com for more inquiries.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.